A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference20 articles.
1. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study;Kereiakes;Am. Heart J.,2015
2. Monotherapy with the PCSK9 inhibitor alirocumab vs. ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial;Roth;Int. J. Cardiol.,2014
3. Alirocumab as add-on to atorvastatin vs. other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial;Bays;J. Clin. Endocrinol. Metab.,2015
4. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events;Robinson;N. Engl. J. Med.,2015
5. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Cited by 96 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of PCSK9 Inhibitors on Lipoprotein(a): A Meta-analysis and Meta-regression of Randomized Controlled Trials;2024-07-11
2. Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study;BMC Medical Research Methodology;2024-06-22
3. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis;European Heart Journal;2024-06-14
4. Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials;Int. Journal of Clinical Pharmacology and Therapeutics;2024-06-01
5. Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat;American Journal of Cardiovascular Drugs;2024-05-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3